10.73
2.54%
-0.28
Handel nachbörslich:
10.98
0.25
+2.33%
Dynavax Technologies Corp. Aktie (DVAX) Neueste Nachrichten
Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
The Motley Fool
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
The Motley Fool
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Zacks Investment Research
Why Vera Therapeutics Stock Soared by 22% This Week
The Motley Fool
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
MarketWatch
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Zacks Investment Research
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
Zacks Investment Research
Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research
Collegium (COLL) Shares Rise on Financial Outlook for 2024
Zacks Investment Research
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
Zacks Investment Research
C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
Zacks Investment Research
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
Zacks Investment Research
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
MarketWatch
Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology
Zacks Investment Research
Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?
Zacks Investment Research
20 favorite small-cap stocks for 2024 among Wall Street analysts
MarketWatch
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
Zacks Investment Research
Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study
Zacks Investment Research
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
Zacks Investment Research
Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?
Zacks Investment Research
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
Zacks Investment Research
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
Zacks Investment Research
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
Zacks Investment Research
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
Zacks Investment Research
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
Zacks Investment Research
Can Dynavax Technologies (DVAX) Climb 91.59% to Reach the Level Wall Street Analysts Expect?
Zacks Investment Research
bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How
Zacks Investment Research
Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?
Zacks Investment Research
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
Zacks Investment Research
Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
Zacks Investment Research
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
Zacks Investment Research
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How
Zacks Investment Research
Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals
Zacks Investment Research
Eli Lilly (LLY) Stock Outperforms Industry YTD: Here's Why
Zacks Investment Research
Merck (MRK) to Acquire Private Neuroscience Company for $610M
Zacks Investment Research
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright
Zacks Investment Research
Vertex (VRTX) Non-Cystic Fibrosis Pipeline Boosts Stock This Year
Zacks Investment Research
Bayer (BAYRY) Stops Heart Drug Study Due to Lack of Efficacy
Zacks Investment Research
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
Zacks Investment Research
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
Zacks Investment Research
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
Zacks Investment Research
CRISPR (CRSP), Vertex Get UK Nod for First Gene Therapy Casgevy
Zacks Investment Research
Bristol Myers (BMY) Receives FDA Approval for NSCLC Drug
Zacks Investment Research
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
Zacks Investment Research
Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate
Zacks Investment Research
Kapitalisierung:
|
Volumen (24h):